REMARKS

Applicant in the November 3, 2003 response elected Group I, claims 1-42 and 52-56, which are drawn to an inhibitor of asparaginyl endopeptidase, pharamaceutical preparations comprising same, methods of making same and methods of modulating an immune response or reducing protein processing in a patient or cell using same. Further, Applicant in the November 3, 2003 response elected the species, "treatment of autoimmune disease," as shown in claims 3, 4, 13, 24, 25 and 40 as required under 35 USC section 121.

Claims 5-7, 21, 26-27 and 43-51 were previously cancelled.

Claim 40 was previously amended in the November 3, 2003 response.

Therefore, claims 1-4, 8-20, 22-25, 28-42, and 52-56 are pending.

Applicant also requests that the Examiner's request for new and formal drawings be held in abeyance until such time as the patent application is allowed. MPEP 608.02(b); 37 CFR 1.85(c).

Accordingly, examination of this application on the merits is respectfully requested.

Respectfully submitted,

Dated: December 15, 2003

Guy P. Smith, Reg. No. 20,142

Attorney for Applicant

OPPENHEIMER WOLFF & DONNELLY LLP

233 Wilshire Blvd., Suite 700 Santa Monica, Ca 90401

Tel: 310.319.5414